[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Talphera Inc (TLPH)

Talphera Inc (TLPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Talphera: Q1 Earnings Snapshot

Talphera: Q1 Earnings Snapshot

TLPH : 0.8318 (+4.33%)
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

NEPHRO CRRT clinical study expected to be completed this year

TLPH : 0.8318 (+4.33%)
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

SAN MATEO, Calif. , May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies...

TLPH : 0.8318 (+4.33%)
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026

SAN MATEO, Calif. , March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies...

TLPH : 0.8318 (+4.33%)
Talphera: Q4 Earnings Snapshot

Talphera: Q4 Earnings Snapshot

TLPH : 0.8318 (+4.33%)
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million

TLPH : 0.8318 (+4.33%)
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026

SAN MATEO, Calif. , March 18, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies...

TLPH : 0.8318 (+4.33%)
Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites

TLPH : 0.8318 (+4.33%)
Talphera: Q3 Earnings Snapshot

Talphera: Q3 Earnings Snapshot

TLPH : 0.8318 (+4.33%)
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc.

TLPH : 0.8318 (+4.33%)
CRMD : 7.82 (-1.14%)

Barchart Exclusives

This High-Yield REIT Just Hiked Its Dividend By 7.1%. Its Shares Look Compelling Here.
Simon Property Group just delivered a solid Q1 beat and raised the quarterly dividend by 7.1% to $2.25 per share, marking its fifth consecutive year of increases. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.